Author:
Dong Yidian,Li Ping,Xu Tingshuang,Bi Liqi
Funder
National key research and development program of China
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Reference32 articles.
1. Davis JC Jr, van der Heijde DM, Braun J et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67:346–352
2. Arends S, Brouwer E, Efde M et al (2017) Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin Exp Rheumatol 35:61–68
3. Ruwaard J, l’Ami MJ, Marsman AF et al (2018) Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab. Scand J Rheumatol 47:122–126
4. Scheinberg MA, Kay J (2012) The advent of biosimilar therapies in rheumatology—“O brave new world”. Nat Rev Rheumatol 8:430–436
5. Dörner T, Strand V, Castañeda-Hernández G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72:322–328
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献